#United States #New York #Lucid Diagnostics #PAVmed #Veris Health

PAVmed Inc. Provides Business Update and Q2 2025 Financial Results

On August 14, 2025, PAVmed Inc. (NASDAQ: PAVM) released its financial outcomes for the second quarter of 2025, unveiling vital updates pertaining to its operations and strategic direction. As a diversified company in medical technology focusing on devices, diagnostics, and digital health solutions, PAVmed operates with key subsidiaries, including Lucid Diagnostics and Veris Health. The recent report demonstrates the company's commitment to growth and product innovation while maintaining transparency with its investors.

Financial Highlights for Q2 2025

The quarter saw PAVmed achieving notable milestones. Operating expenses totaled around $4.7 million, including $0.2 million in stock-based compensation. However, the net loss attributable to shareholders was approximately $13.3 million, translating to $(0.74) per diluted share. In comparison, the non-GAAP adjusted loss was about $1.8 million or $(0.11) per share, indicating a keen focus on clarifying financial performance excluding non-cash items.

The latest report also disclosed cash and cash equivalents of $4.0 million by the end of June 2025, a significant increase from $1.2 million at the close of 2024. This improvement bodes well for the company's operational resilience moving forward, extending its financial runway into 2026 thanks to a successful public offering that netted approximately $16.1 million.

Major Developments in Subsidiaries

PAVmed's strategic subsidiaries made impressive strides during the period:

• - Lucid Diagnostics recognized revenue of $1.2 million from its EsoGuard® Esophageal DNA Test, processing 2,756 tests in total. The company is preparing for a crucial Contractor Advisory Committee (CAC) meeting scheduled for September 4, 2025, focusing on Medicare policy.
• - In a landmark progression, Lucid initiated patient testing under the first commercial insurance coverage policy for EsoGuard, signifying a promising advance in its healthcare integration.

• - Veris Health completed a direct equity financing of $2.5 million, optimizing its capital structure to support the development of its innovative implantable physiological monitor, which is an integral part of its ongoing enhancement of cancer care.
• - The partnership between Veris and The Ohio State’s James Cancer Hospital aims to integrate its cancer care platform with OSU's electronic health record system, which is anticipated to streamline patient monitoring and care processes.

Strategic Vision Ahead

Lishan Aklog, M.D., Chairman and CEO of PAVmed, emphasized, “We have stabilized our corporate structure and strengthened our financial position, allowing us to push forward as a comprehensive life sciences company with diverse subsidiaries.” This statement underlines PAVmed's intention to leverage its subsidiaries and assess new opportunities to expand its portfolio continuously.

PAVmed remains focused on diversifying its offerings and improving patient outcomes through innovative technological solutions. As it explores partnerships with academic medical centers centered on innovative technologies, the company is poised for future growth.

Conclusion and Future Outlook

PAVmed's continuous efforts to secure its financial standing and expand its technological innovations illustrate its commitment to providing valuable solutions in the healthcare sector. As it heads into the next quarter, all eyes will be on the company’s approach to navigating regulatory landscapes, advancing product offerings, and managing operational execution amid fluctuating market conditions. Investors and stakeholders are encouraged to participate in the upcoming conference call scheduled for August 14, reflecting on the developments and insights into PAVmed's path forward.

For more detailed financial information and the latest updates, please visit PAVmed's official website at pavmed.com.